viewFaron Pharmaceuticals Ltd

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine results in Q2

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products.

Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment for Acute Respiratory Distress Syndrome (ARDS).

Results from a phase III trial (INTEREST) are expected early in the spring, but Faron's keen to lay the groundwork for a product launch.

The money will also enable Faron to expand the scope of the upcoming phase I/IIb trial of immunotherapy cancer treatment Clevegen.

Quick facts: Faron Pharmaceuticals Ltd

Price: 405 GBX

Market: AIM
Market Cap: £189.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...


Faron Pharmaceuticals boss upbeat as Phase III trial enters critical period

Dr Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN) tells Proactive's Andrew Scott they're entering an exciting period for the company with recruitment for their Phase III trial for its lead drug set for completion later this year. A positive readout for...

on 6/9/17

2 min read